Thus, we use here the allosteric inhibitor SHP099 (Garcia Fortanet et al., 2016) to study the role of SHP2 on phosphoprotein dynamics at the whole proteome level following EGF stimulation of a breast cancer cell line carrying an EGFR amplification. Here, PTPN11 is linked to breast cancer.